MaxCyte, Inc. Notice of AGM (2057D)
October 08 2018 - 2:00AM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 2057D
MaxCyte, Inc.
08 October 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notification of Annual General Meeting
Gaithersburg, MD - 08 October 2018: MaxCyte (LSE: MXCT, MXCR),
the global cell-based medicines and life sciences company,
announces that formal notice and resolutions of the Company's
Annual General Meeting (AGM), along with the Annual Meeting Proxy
Card and Form of Direction, has been circulated to
Shareholders.
These documents are also available in electronic form on the
Company's website: www.maxcyte.com.
The Annual General Meeting of Stockholders is planned to be held
at 11 a.m. EDT on 31 October 2018 at 21 Firstfield Road, Suite 202,
Gaithersburg, MD 20878, USA.
About MaxCyte
MaxCyte is a global cell-based medicines and life sciences
company applying its patented cell engineering technology to help
patients with high unmet medical needs in a broad range of
conditions. MaxCyte is developing novel CARMA(TM) therapies for its
own pipeline. CARMA is MaxCyte's mRNA-based proprietary platform
for autologous cell therapy. In addition, through its core
business, the Company leverages its Flow Electroporation(R)
Technology to enable its partners across the biopharmaceutical
industry to advance the development of innovative medicines,
particularly in cell therapy, including gene editing and
immuno-oncology. The Company has placed its cutting-edge flow
electroporation instruments worldwide, with all of the top ten
global biopharmaceutical companies, has more than 55 partnered
programme licences in cell therapy including more than 25 licensed
for clinical use. With its robust delivery technology, MaxCyte
helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com
For more information, visit www.maxcyte.com.
###
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Ryan McCarthy
Corporate Broking
James Stearns +44 (0)20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NOADGBDGIXGBGIR
(END) Dow Jones Newswires
October 08, 2018 02:00 ET (06:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2024 to Jun 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2023 to Jun 2024